Published in:
01-10-2005 | Adis Drug Profile
Lansoprazole
In the Treatment of Gastro-oesophageal Reflux Disease in Children and Adolescents
Published in: Drugs | Issue 15/2005
Login to get accessAbstract
▴ Lansoprazole is a proton pump inhibitor that inactivates the H+/K+-ATPase pump in parietal cells, thus inhibiting gastric acid secretion and increasing intragastric pH.
▴ In an open-label, uncontrolled trial in children aged 1–11 years with gastro-oesophageal reflux disease (GORD), treatment with lansoprazole 15 or 30mg (depending on weight) once daily for 8–12 weeks improved symptoms compared with baseline in 76% of patients (47 of 62) based on patient diaries and healed erosive oesophagitis (confirmed endoscopically) in all 27 children who had it at baseline.
▴ In adolescents aged 12–17 years with GORD, 8 weeks’ treatment with lansoprazole 15mg (in 64 patients with nonerosive disease) or 30mg (in 23 patients with erosive oesophagitis) once daily reduced the frequency and severity of symptoms by 63% and 69% compared with baseline, based on patient diaries. In this open-label, uncontrolled trial, 96% of evaluable patients with erosive disease (21 of 22) had mucosal healing by week 8, as confirmed by endoscopy; mucosal healing did not occur after an additional 4 weeks’ treatment in one patient.
▴ Lansoprazole was generally well tolerated in children and adolescents, with the most common treatment-related adverse events being gastrointestinal events and headache.